IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas-Reference-Cited by-同舟云学术

IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas

Published:2021-05 Issue: Volume:221 Page:153445
ISSN:0344-0338
Container-title:Pathology - Research and Practice
language:en
Short-container-title:Pathology - Research and Practice

Author:

Franceschi Enrico^ORCID,Biase Dario De,Di Nunno Vincenzo^ORCID,Pession Annalisa,Tosoni Alicia,Gatto Lidia,Lodi Raffaele,Tallini Giovanni,Visani Michela,Bartolini Stefania^ORCID,Brandes Alba Ariela

Publisher

Elsevier BV

Subject

Cell Biology,Pathology and Forensic Medicine

Reference34 articles.

1. Molecular pathways: isocitrate dehydrogenase mutations in Cancer;Clark;Clin. Cancer Res.,2016

2. IDH1 and IDH2 mutations in gliomas;Yan;N. Eng. J. Med.,2009

3. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival;Leu;Neuro. Oncol.,2013

4. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas;Olar;Acta Neuropathol.,2015

5. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT;Pekmezci;Acta Neuropathol.,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor Microenvironment in Gliomas: A Treatment Hurdle or an Opportunity to Grab?;Cancers;2023-02-07

2. Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma;Genes;2022-08-12

3. Ferroptosis in Intrahepatic Cholangiocarcinoma: IDH1105GGT Single Nucleotide Polymorphism Is Associated With Its Activation and Better Prognosis;Frontiers in Medicine;2022-07-08

4. Tumor-Associated Microenvironment of Adult Gliomas: A Review;Frontiers in Oncology;2022-07-07

5. Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes;JNCI: Journal of the National Cancer Institute;2022-04-27